Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 6, 2012, Pages 621-630

  Endo, Shinya ^a   Toyoda, Yasuyuki ^a   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Adverse drug reactions; Bioactivation; CYP3A4; Drug induced hepatotoxicity; Inflammation; Monocytes macrophages

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFOXIDE; AMIODARONE; CD86 ANTIGEN; CYTOCHROME P450 3A4; DEETHYLAMIODARONE; DESIPRAMINE; DICLOFENAC; HYDRALAZINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; KETOCONAZOLE; LEFLUNOMIDE; NEFAZODONE; TACRINE; TAMOXIFEN; TERBINAFINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL STIMULATION; CELL STRAIN THP 1; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LEUKEMIA CELL LINE; LIVER MICROSOME; METABOLIC ACTIVATION; MONOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXIC HEPATITIS; UPREGULATION;

EID: 84871707726     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-019     Document Type: Article

References (44)

1. Guengerich, F. P. and McDonald, J. S.: Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol., 20: 344-369 (2007).
2. Adams, D. H., Ju, C., Ramaiah, S. K., Uetrecht, J. and Jaeschke, H.: Mechanisms of immune-mediated liver injury. Toxicol. Sci., 115: 307-321 (2010).
3. Holt, M. P. and Ju, C.: Mechanisms of drug-induced liver injury. AAPS J., 8: E48-E54 (2006).
4. Lee, W. M.: Drug-induced hepatotoxicity. N. Engl. J. Med., 349: 474-485 (2003).
5. Guengerich, F. P.: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 39: 1-17 (1999).
6. Hosomi, H., Fukami, T., Iwamura, A., Nakajima, M. and Yokoi, T.: Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab. Dispos., 39: 1388-1395 (2011).
7. Eliasson, E., Gardner, I., Hume-Smith, H., de Waziers, I., Beaune, P. and Kenna, J. G.: Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Chem. Biol. Interact., 116: 123-141 (1998).
8. Sanderson, J. P., Naisbitt, D. J., Farrell, J., Ashby, C. A., Tucker, M. J., Rieder, M. J., Pirmohamed, M., Clarke, S. E. and Park, B. K.: Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J. Immunol., 178: 5533-5542 (2007).
9. Higuchi, S., Kobayashi, M., Yano, A., Tsuneyama, K., Fukami, T., Nakajima, M., et al.: Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. J. Appl. Toxicol., 32: 815-822 (2011).
10. Higuchi, S., Kobayashi, M., Yoshikawa, Y., Tsuneyama, K., Fukami, T., Nakajima, M., et al.: IL-4 mediates dicloxacillininduced liver injury in mice. Toxicol. Lett., 200: 139-145 (2011).
11. Kobayashi, M., Higuchi, S., Mizuno, K., Tsuneyama, K., Fukami, T., Nakajima, M., et al.: Interleukin-17 is involved in αnaphthylisothiocyanate-induced liver injury in mice. Toxicology, 275: 50-57 (2010).
12. Kobayashi, E., Kobayashi, M., Tsuneyama, K., Fukami, T., Nakajima, M. and Yokoi, T.: Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci., 111: 302-310 (2009).
13. Toyoda, Y., Endo, S., Tsuneyama, K., Miyashita, T., Yano, A., Fukami, T., et al.: Mechanism of exacerbative effect of progesterone on drug-induced liver injury. Toxicol. Sci., 126: 16-27 (2011).
14. Toyoda, Y., Miyashita, T., Endo, S., Tsuneyama, K., Fukami, T., Nakajima, M., et al.: Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol. Lett., 204: 17-24 (2011).
15. Bradham, C. A., Plümpe, J., Manns, M. P., Brenner, D. A. and Trautwein, C.: Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am. J. Physiol., 275: G387-G392 (1998).
16. Baggiolini, M., Dewald, B. and Moser, B.: Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol., 55: 97-179 (1994).
17. Leonard, E. J., Yoshimura, T., Tanaka, S. and Raffeld, M.: Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1. J. Invest. Dermatol., 96: 690-694 (1991).
18. You, Q., Cheng, L., Reilly, T. P., Wegmann, D. and Ju, C.: Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology, 44: 1421-1431 (2006).
19. Edling, Y., Sivertsson, L. K., Butura, A., Ingelman-Sundberg, M. and Ek, M.: Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol. In Vitro, 23: 1387-1395 (2009).
20. Edling, Y., Sivertsson, L., Andersson, T. B., Porsmyr-Palmertz, M. and Ingelman-Sundberg, M.: Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. Toxicol. In Vitro, 22: 1588-1594 (2008).
21. Mizuno, K., Toyoda, Y., Fukami, T., Nakajima, M. and Yokoi, T.: Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. Arch. Toxicol., 85: 199-207 (2011).
22. Mizuno, K., Fukami, T., Toyoda, Y., Nakajima, M. and Yokoi, T.: Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway. Life Sci., 87: 537-544 (2010).
23. Sakaguchi, H., Ashikaga, T., Miyazawa, M., Yoshida, Y., Ito, Y., Yoneyama, K., et al.: Development of an in vitro skin sensitization test using human cell lines; human cell line activation test (h-CLAT). II. An inter-laboratory study of the h-CLAT. Toxicol. In Vitro, 20: 774-784 (2006).
24. Becker, D., Kolde, G., Reske, K. and Knop, J.: An in vitro endocytotic activation of murine epidermal Langerhans cells under the influence of contact allergens. J. Immunol. Methods, 169: 195-204 (1994).
25. Miyazawa, M., Ito, Y., Yoshida, Y., Sakaguchi, H. and Suzuki, H.: Phenotypic alterations and cytokine production inTHP-1 cells in response to allergens. Toxicol. In Vitro, 21: 428-437 (2007).
26. Ohyama, K., Nakajima, M., Nakamura, S., Shimada, N., Yamazaki, H. and Yokoi, T.: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab. Dispos., 28: 1303-1310 (2000).
27. Yoshida, Y., Sakaguchi, H., Ito, Y., Okuda, M. and Suzuki, H.: Evaluation of the skin sensitization potential of chemicals using expression of co-stimulatory molecules, CD54 and CD86, on the naïve THP-1 cell line. Toxicol. In Vitro, 17: 221-228 (2003).
28. Gottschall, D. W., Theodorides, V. J. and Wang, R.: The metabolism of benzimidazole anthelmintics. Parasitol. Today, 6: 115-124 (1990).
29. Rawden, H. C., Kokwaro, G. O., Ward, S. A. and Edwards, G.: Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br. J. Clin. Pharmacol., 49: 313-322 (2000).
30. McCarthy, T. C., Pollak, P. T., Hanniman, E. A. and Sinal, C. J.: Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-α target gene activation. J. Pharmacol. Exp. Ther., 311: 864-873 (2004).
31. O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., et al.: High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol., 80: 580-604 (2006).
32. Trompezinski, S., Migdal, C., Tailhardat, M., Le Varlet, B., Courtellemont, P., Haftek, M., et al.: Characterization of early events involved in human dendritic cell maturation induced by sensitizers: cross talk between MAPK signalling pathways. Toxicol. Appl. Pharmacol., 230: 397-406 (2008).
33. Mitjans, M., Viviani, B., Lucchi, L., Galli, C. L., Marinovich, M. and Corsini, E.: Role of p38 MAPK in the selective release of IL-8 induced by chemical allergen in naive THP-1 cells. Toxicol. In Vitro, 22: 386-395 (2008).
34. Waldhauser, K. M., Torok, M., Ha, H. R., Thomet, U., Konrad, D., Brecht, K., et al.: Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther., 319: 1413-1423 (2006).
35. Breuer, H. W., Bossek, W., Haferland, C., Schmidt, M., Neumann, H. and Gruszka, J.: Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int. J. Clin. Pharmacol. Ther., 36: 350-352 (1998).
36. Lewis, J. H., Mullick, F., Ishak, K. G., Ranard, R. C., Ragsdale, B., Perse, R. M., et al.: Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum. Pathol., 21: 59-67 (1990).
37. Zahno, A., Brecht, K., Morand, R., Maseneni, S., T'r'k, M., Lindinger, P. W., et al.: The role of CYP3A4 in amiodaroneassociated toxicity on HepG2 cells. Biochem. Pharmacol., 81: 432-441 (2011).
38. Futamura, Y.: Effect of amiodarone on cytokine release and on enzyme activities of mouse alveolar macrophages, bone marrow macrophages, and blood monocytes. J. Toxicol. Sci., 21: 125-134 (1996).
39. Stäubli, M., Bircher, J., Galeazzi, R. L., Remund, H. and Studer, H.: Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur. J. Clin. Pharmacol., 24: 485-494 (1983).
40. Lalloz, M. R., Byfield, P. G., Greenwood, R. M. and Himsworth, R. L.: Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J. Pharm. Pharmacol., 36: 366-372 (1984).
41. Berger, Y. and Harris, L.: Pharmacokinetics. In: Harris, L. and Roncucci, R. (eds.): Amiodarone: Pharmacology, Pharmacokinetics, Toxicology, and Clinical Effects, Paris, Medecine et Science Internationales, 1986, pp. 45-98.
42. Latini, R., Tognoni, G. and Kates, E. R.: Clinical pharmacokinetics of amiodarone. Clin. Pharmacokinet., 9: 136-156 (1984).
43. Ha, H. R., Bigler, L., Wendt, B., Maggiorini, M. and Follath, F.: Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur. J. Pharm. Sci., 24: 271-279 (2005).
44. Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H. and Yokoi, T.: Inhibitory effects of amiodarone and its Ndeethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol., 49: 244-253 (2000).